CFDE Data Portal | Search STARD4-AS1

	Label	Description
	STARD4-AS1 Gene (Entity type)	ENSG00000246859 - STARD4 antisense RNA 1
	STARD4-AS1 associations Collection (Entity type)	Associations for STARD4-AS1_associations
	STARD4-AS1 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	GSE168473 0 V 1 ISONIAZID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE203362 0 V 1 ENZALUTAMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE226249 pirfenidone HL 0 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE200982 PLAC8 knockout 0 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE212231 GSE218491 SHP2 inhibition 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE146358 dopamine 3 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS

STARD4-AS1

ENSG00000246859 - STARD4 antisense RNA 1

STARD4-AS1 associations

Associations for STARD4-AS1_associations

STARD4-AS1 associations.tsv

A file from IDG as part of the Harmonizome project

GSE168473 0 V 1 ISONIAZID HUMAN UP

A Gene Set from LINCS

GSE203362 0 V 1 ENZALUTAMIDE HUMAN DN

A Gene Set from LINCS

GSE226249 pirfenidone HL 0 v 7 human dn

A Gene Set from LINCS

GSE200982 PLAC8 knockout 0 v 2 human dn

A Gene Set from LINCS

GSE212231 GSE218491 SHP2 inhibition 3 v 5 human up

A Gene Set from LINCS

GSE146358 dopamine 3 v 7 human dn

A Gene Set from LINCS

GSE195663 cisplatin 0 v 1 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.